



## MEDIA RELEASE

# Cordlife Indonesia extends stem cell cryogenic storage service to leukaemia patients from Dharmais Cancer Hospital in support of cellular therapy

- Dharmais Cancer Hospital, the National Cancer Centre in Indonesia, will leverage on Cordlife's expertise in stem cell cryogenic storage service to provide cellular therapy for patients with leukaemia.
- Cellular therapy is an alternative cancer treatment that has been shown to improve the survival rate of leukaemia patients.

**SINGAPORE, 10 January 2022** – Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”), a Singapore Exchange mainboard listed company, announced that its Indonesian subsidiary, PT. Cordlife Persada (“Cordlife Indonesia”), is partnering with Dharmais Cancer Hospital, Indonesia’s National Cancer Centre, to provide stem cell cryogenic storage services for adult leukaemia patients who may require cellular therapy if chemotherapy fails to eradicate cancer cells.

Dharmais Cancer Hospital is one of the few hospitals in Indonesia that offers cellular therapy as an alternative treatment for adult leukaemia patients. The collaboration aims to harness Cordlife’s vast experience and expertise in stem cell cryopreservation and cryogenic storage. Cordlife Indonesia will provide cryogenic storage services for peripheral blood stem cells and peripheral blood lymphocyte cells, which will be used in cellular therapies. Dharmais Cancer Hospital has existing facility to enable the collection and processing of the therapeutic cells.

Leukaemia is a disorder in which the bone marrow produces an excessive amount of abnormal white blood cells that do not function properly. According to the International Agency for Research on Cancer, leukaemia is one of the most common cancers in Indonesia, accounting for 4.9 percent of cancer deaths in 2020 and a 5-year prevalence rate of 15.25 per 100,000 patients.<sup>1</sup>

Chemotherapy is currently the most common treatment for leukaemia. This treatment involves infusing drugs into patients’ bodies to destroy cancer cells. However, the cancer may sometimes return after a remission period as chemotherapy may not have eradicated all cancer cells. In these cases, the doctors at Dharmais Cancer Hospital can use cellular therapy, such as stem cell transplantation, to treat patients. One of the goals of cellular therapy is to boost the immune system’s ability to fight cancer. These transplants can be either autologous (using the patient’s own stem cell) or allogeneic (using a donor’s stem cells). The haematologist and oncologist will jointly assess the

---

<sup>1</sup> South-Eastern Asia - Global Cancer Observatory (<http://gco.iarc.fr/today/data/factsheets/populations/920-south-eastern-asia-fact-sheets.pdf>)



patients' suitability for cellular therapy. Stem cells from a donor will also be tested for compatibility to lower the risk of side effects and improve the odds of transplant success.

As one of the oldest cord blood banks in Asia with over 20 years of experience in stem cell cryopreservation, Cordlife has established itself as one of the leading cord blood banks in the world. Cordlife also operates the largest network of cord blood banks in Asia. All of Cordlife's facilities and processes are accredited by the Association for the Advancement of Blood & Biotherapies ("AABB"), which is regarded as the global leader in the development of cord blood banking standards. Cordlife Indonesia is the first cord blood bank in Indonesia to receive this accreditation.

"We are excited to partner Dharmais Cancer Hospital for the treatment of leukaemia using cellular therapy. Through this partnership, we hope to be able to reach out and help patients with leukaemia on the road to recovery," said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife.

### End ###

## ABOUT CORDLIFE GROUP LIMITED

Established in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a leading company dedicated to safeguarding the well-being of mother and child. The Group is listed on the Mainboard of the Singapore Exchange in 2012 and is a pioneer in private cord blood banking in Asia. Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and it is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife has also established its presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh. Beyond cord blood, cord lining and cord tissue banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services. Quality and customer focus are amongst some of the cornerstones of Cordlife. For more information, visit <http://cordlife.listedcompany.com>.

## ABOUT PT. CORDLIFE PERSADA

PT Cordlife Persada ("Cordlife Indonesia" or the "Company") is a majority-owned subsidiary of Cordlife Group Limited. Established in Indonesia since 2003, Cordlife Indonesia is the first company in the country to operate a full-fledged cord blood processing and cryopreservation facility locally. According to Deloitte, the Company has grown to become Indonesia's market leader in cord blood banking. Their facility located in central Jakarta is currently the largest stem cell banking facility in Indonesia with storage capacity of up to 70,000 stem cell units. The facility is also accredited by the



Association for the Advancement of Blood & Biotherapies (AABB), which is regarded as the global leader in the development of cord blood banking standards. Cordlife's facility also has dedicated laboratory areas where diagnostic testing can be performed. For more information, visit [www.cordlife.co.id](http://www.cordlife.co.id).

---

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR  
4 Robinson Road #04-01  
The House of Eden  
Singapore 048543

CONTACT : Mr Kamal Samuel  
Mr Maverick Lim

OFFICE : (65) 6438 2990

EMAIL : [kamal@financialpr.com.sg](mailto:kamal@financialpr.com.sg)  
[maverick@financialpr.com.sg](mailto:maverick@financialpr.com.sg)